Research Topic · Peer-Reviewed

Hematological-malignancies

Hematological malignancies are cancers that arise from cells of the blood, bone marrow, and lymphatic system, originating in the hematopoietic and lymphoid lineages rather than forming solid organ tumors. They are broadly classified into leukemias, which involve clonal proliferation of myeloid or lymphoid precursors…

Curated from this journal's research 📚 7 peer-reviewed articles cited Cited 21× across the literature 🗓 Reviewed June 2026

Overview

Hematological malignancies are cancers that arise from cells of the blood, bone marrow, and lymphatic system, originating in the hematopoietic and lymphoid lineages rather than forming solid organ tumors. They are broadly classified into leukemias, which involve clonal proliferation of myeloid or lymphoid precursors in the marrow and blood; lymphomas, which develop in lymph nodes and lymphoid tissues and include Hodgkin and non-Hodgkin subtypes; and plasma cell disorders such as multiple myeloma and Waldenström's macroglobulinemia, marked by malignant antibody-producing cells. These diseases arise from acquired genetic and epigenetic alterations that disrupt normal differentiation, proliferation, and apoptosis, with leukemogenesis often driven by mutations, chromosomal translocations, and dysregulated signaling in hematopoietic stem and progenitor cells. Surface markers and molecular profiles are central to classification and diagnosis, and aberrant expression of receptors and signaling proteins can distinguish malignant clones. Hematological malignancies may also perturb hemostasis, producing acquired coagulation abnormalities, and can present with paraneoplastic syndromes affecting other organ systems. Diagnosis integrates morphology, immunophenotyping, cytogenetics, and molecular testing, while management spans chemotherapy, targeted agents, immunotherapy, and stem cell transplantation. Research in this area examines the molecular markers, microenvironmental interactions, and clonal evolution that govern disease behavior, prognosis, and the response to therapy.

Research published in this journal

7 peer-reviewed articles, ranked by relevance. Each links to its DOI.

How this research is being cited

The 7 articles above have been cited 21 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Hematological-malignancies, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Advances in Leukemia.

Journal editorial board
Hang Su · United States Ewelina Grywalska · Poland Antonio Ruggiero · Italy

This page summarises published research for orientation; it is not medical or professional advice.